Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 27 tags : Drug save search
Eli Lilly and Pfizer Put Osteoarthritis Pain Drug Out of its Misery
Published: 2021-10-27 (Crawled : 17:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.59%
H: 0.05%
C: -1.17%
drug osteoarthritis
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
Published: 2021-10-27 (Crawled : 14:15) - biospace.com/
LTRN | $5.87 -2.0% -2.04% 110K
|
Health Technology
|
| O: -0.18%
H: 0.37%
C: -6.98%
collaboration computational drug research
Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 1.15%
H: 1.13%
C: -3.77%
drug trial
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
Published: 2021-10-27 (Crawled : 13:00) - prnewswire.com
LTRN | $5.87 -2.0% -2.04% 110K
|
Health Technology
|
| O: -0.18%
H: 0.37%
C: -6.98%
collaboration computational drug research
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
APVO 3 d | $0.76 6.67% 6.25% 220K
|
Health Technology
|
| O: -0.96%
H: 2.83%
C: 0.69%
drug leukemia conference apvo436
Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
LTRN | $5.87 -2.0% -2.04% 110K
|
Health Technology
|
| O: -0.18%
H: 0.37%
C: -6.98%
computational drug research
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2021-10-27 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M
|
Health Technology
|
| O: 0.44%
H: 7.18%
C: 4.57%
covid new drug fda application vaccine drug phase 3 trial submission bbv152
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.